August 26, 2016
GlycoBiomarker Leading Innovation Co. Ltd.
Receipt of the 14th Annual Merit Award from the Minister of Economy, Trade and Industry for Collaborative Achievement in Industry, Academia and Government
The 14th Minister of Economy, Trade and Industry (METI) Merit Award for the industry, academia, government collaboration achievement was given to our CTO and Prime Senior Researcher, Glycomedicine R&D Group, Dr. Atsushi Kuno (National Institute of Advanced Industrial Science and Technology [AIST] Chief senior researcher, Biotechnology Research Institute for Drug Discovery), AIST Principal research manager of Biotechnology Research Institute for Drug Discovery, Dr. Hisashi Narimatsu, and Executive vice president of Immunology & Chemistry Product Engineering Division, ICH Business Unit, Sysmex Corporation (Sysmex), Dr. Yoichi Takahama.
The Annual Merit Award for Industry, Academia and Government Collaborative Achievement was introduced in 2003 to recognize major success in industry–academia–government collaboration among companies, universities and public-sector research institutions successfully demonstrating substantial contribution through the promotion of leading-edge initiatives to help promote further industry–academia–government collaboration in Japan. The METI award is one of 12 awards bestowed from different ministries and agencies including the Prime Minister’s Award.
World’s first practical realization of a system for diagnosing hepatic fibrosis using glycosylation
|Hisashi Narimatsu||(Principal Research Manager, Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology)|
|Atsushi Kuno||(Chief Senior Researcher, Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology)|
|Yoichi Takahama||(Executive Vice President, Immunology & Chemistry Product Engineering Division, ICH Business Unit, Sysmex Corporation)|
Intensive collaboration of the AIST, commercial company, and clinical institution network enabled rapid implementation of development, pharmaceutical approval, medical insurance coverage, and international distribution.
Cabinet Office website (Japanese)
GlycoBiomarker Leading Innovation Co. Ltd. (GL-i)
1-1-1 Umezono, Tsukuba, Ibaraki 305-8568 Japan
E-mail: email@example.com / URL: http://www.gl-i.co.jp/